Table 1.
Baseline characteristics of included patients at the time of their first recorded visit with anaemia treatment
| Covariates | Overall |
|---|---|
| n | 5000 |
| Age, mean (SD), years | 69 (15) |
| Women | 2229 (45) |
| BMI, kg/m2 | 26.6 (23.5–30.8) |
| CKD stages, mL/min/1.73 m2 | |
| G3b 30–44 | 825 (16) |
| G4 15–29 | 2442 (49) |
| G5 <15 | 1733 (35) |
| CKD aetiology | |
| Diabetic nephropathy | 1266 (25) |
| Nephrosclerosis | 1190 (24) |
| Glomerulonephritis | 503 (10) |
| Pyelonephritis | 130 (3) |
| Polycystic kidney disease | 260 (5) |
| Other | 979 (20) |
| Unknown | 672 (13) |
| Kidney transplanted | 78 (2) |
| Comorbidities, n (%) | |
| Hypertension | 4380 (88) |
| Diabetes mellitus | 2253 (45) |
| CVD | 2650 (53) |
| Medications, n (%) | |
| Initial anaemia treatment | |
| Only iron (IV or oral) | 1998 (40) |
| Only ESA | 2066 (41) |
| ESA dose (IU/week) | 4000 (2200–5874) |
| Iron and ESA | 936 (19) |
| ESA dose (IU/week) | 4000 (2800–6000) |
| Statin | 2900 (58) |
| Sodium bicarbonate | 2336 (47) |
| Chemistry, median (IQR) | |
| hsCRP, mg/L | 5.0 (2.0–10.0) |
| Ca2+, mmol/L | 2.3 (2.2–2.4) |
| PO4−, mmol/L | 1.3 (1.2–1.6) |
| PTH, ng/L | 16.4 (10.0–27.0) |
| Albumin, g/L | 37 (34–39) |
Data are presented as mean (SD), median (IQR) or counts (proportion), as appropriate.
Ca2+, calcium; PO4−, phosphate; PTH, parathyroid hormone.